Request Demo

Last update 08 May 2025

BST1

Last update 08 May 2025

Basic Info

Synonyms

ADP-ribosyl cyclase 2, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2, Bone marrow stromal antigen 1

+ [7]

Introduction

Catalyzes both the synthesis of cyclic ADP-beta-D-ribose (cADPR) from NAD(+), and its hydrolysis to ADP-D-ribose (ADPR) (PubMed:7805847). Cyclic ADPR is known to serve as an endogenous second messenger that elicits calcium release from intracellular stores, and thus regulates the mobilization of intracellular calcium (Probable). May be involved in pre-B-cell growth (Probable).

Drugs associated with BST1

Anti-BST1 antibody(BioLegend)

Target

BST1

Mechanism

BST1 inhibitors

Active Org.

BioLegend, Inc.

Originator Org.

BioLegend, Inc.

Active Indication

Hemoglobinuria, Paroxysmal

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

NC-B8

Target

BST1

Mechanism

BST1 inhibitors

Active Org.

ENCEFA

Originator Org.

ENCEFA

Active Indication

Alzheimer Disease [+3]

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

OBT-357

Target

BST1

Mechanism

BST1 inhibitors [+1]

Active Org.-

Originator Org.

A. Menarini Industrie Farmaceutiche Riunite Srl

Active Indication-

Inactive Indication

Refractory acute myeloid leukemia [+1]

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with BST1

NCT02353143

/ TerminatedPhase 1

First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia.

The purpose of this study is to assess the safety of MEN1112, given as intravenous infusion, in patients with relapsed or refractory AML. Pharmacokinetics, clinical activity and potential immunogenicity of MEN1112 will be evaluated as well.

Start Date01 Dec 2014

Sponsor / Collaborator

A. Menarini Industrie Farmaceutiche Riunite Srl

100 Clinical Results associated with BST1

100 Translational Medicine associated with BST1

0 Patents (Medical) associated with BST1

296

Literatures (Medical) associated with BST1

04 Apr 2025·Journal of Proteome Research

Urine Measurements of the Renin-Angiotensin System-Regulated Proteins Predict Death and Graft Loss in Kidney Transplant Recipients Enrolled in a Ramipril versus Placebo Randomized Controlled Trial

Article

Author: Kotlyar, Max ; Farkona, Sofia ; Knoll, Greg ; Jurisica, Igor ; Burns, Kevin ; Brinc, Davor ; Konvalinka, Ana

The renin-angiotensin system (RAS) is involved in kidney fibrosis. We previously identified six RAS-regulated proteins (RHOB, BST1, LYPA1, GLNA, TSP1, and LAMB2) that were increased in the urine of patients with kidney allograft fibrosis, compared to patients without fibrosis. We hypothesized that these urinary RAS-regulated proteins predicted primary outcomes in kidney transplant recipients enrolled in the largest RAS inhibitor randomized controlled trial. Urine excretion of 10 peptides corresponding to the six RAS-regulated proteins was quantified using parallel reaction monitoring mass spectrometry assays (normalized by urine creatinine) in a subset of patients in the trial. Machine learning models predicting outcomes based on urine peptide excretion rates were developed and evaluated. Urine samples (n = 111) from 56 patients were collected at 0, 6, 12, and 24 months. Twenty-four primary outcomes (doubling of serum creatinine, graft loss, or death) occurred in 17 patients. Logistic regression utilizing eight peptides of TSP1, BST1, LAMB2, LYPA1, and RHOB, from the last urine sample prior to outcomes, predicted a graft loss with an AUC of 0.78 (p = 0.00001). A random forest classifier utilizing BST1 and LYPA1 peptides predicted death with an AUC of 0.80 (p = 0.0016). Urine measurements of RAS-regulated proteins may predict outcomes in kidney transplant recipients, although further prospective studies are required.

01 Apr 2025·Journal of Dairy Science

Epidemiological and genetic factors affecting severe epizootic hemorrhagic disease in Spanish Holstein cattle during the Southern Europe outbreak of 2023

Article

Author: González-Recio, O ; Fernández, A ; Jiménez Montero, J A

Epizootic hemorrhagic disease (EHD) is a noncontagious viral infection that can cause important economic losses on dairy farms. This study aimed to identify epidemiological and genetic factors influencing the susceptibility and severity of EHD in Holstein dairy cattle during the 2023 outbreak in Spain. Data from 2,852 animals in 7 affected farms from 5 Spanish provinces were used. Symptoms were categorized in 5 categories: no symptoms, mild symptoms, severe symptoms and recovery, severe symptoms with aftereffects (sequelae), and severe symptoms followed by death. All animals were genotyped using the Illumina EuroG MD SNP array, and imputation to whole-genome sequencing was carried out using the 1,000 bull genomes dataset as a reference. Risk factors for EHD were explored using linear mixed effects models, as well as the loss of milk yield and culling risk probability due to severe EHD. In all, ∼66% of animals showed EHD virus antibodies, although only 25% of the sample in this study showed severe symptoms, and the death rate was 2% to 3%. Results indicated that age was the main risk factor for severe EHD, with older cows showing greater susceptibility. Production losses were significant in cows with moderate to severe symptoms, especially if the outbreak occurred mid lactation (up to -9 kg/d). Cows exhibiting severe symptoms demonstrated a markedly increased likelihood of being culled, with an odds ratio of 10.86 (95% CI: 6.08-19.41) for cows with severe symptoms. The genetic component of EHD was evaluated using REML procedures, and a GWAS was conducted to investigate genomic regions associated with the disease. An h² of 0.08 was estimated, with some genes (AOC1, BST1, CD38, DPP6, DPYS, HOGA1, KMT2C, PIK2A, PIK3, and PI4K2A) associated with the disease showing involvement in immunity processes and the development of the pulmonary tree. This study underscores the genetic and epidemiological factors influencing EHD severity in dairy cattle, providing insights for managing future outbreaks and mitigating economic losses in affected regions.

01 Mar 2025·American Journal of Reproductive Immunology

Finding Potential Drug Targets for Pre‐Eclampsia Using Mendelian Randomisation and Colocalisation Analysis

Article

Author: Zhao, Tingting ; Wu, Chengqian ; Pan, Yingzi ; Ji, Xiaohong ; Xu, Yuexin ; Miao, Jiayan

ABSTRACTIntroductionPre‐eclampsia (PE) is a common complication of pregnancy and there is an urgent need for new drug targets. We performed whole proteome‐wide Mendelian randomisation (MR) and colocalisation analyses to identify potential therapeutic targets for PE.Material and MethodsA two‐sample MR study was conducted using summary‐level statistics of 734 plasma proteins retrieved from large genome‐proteome‐wide association studies. The summary statistics of PE or eclampsia were obtained from the FinnGen consortium. Wald ratio and Inverse variance weighted (IVW) were used to assess the causal association between proteins and PE. Colocalisation analyses were conducted to examine whether the identified proteins and PE shared incidental variants.ResultsGenetically predicted circulating levels of 42 proteins were associated with PE risk after Benjamini‐Hochberg correction. Nineteen of the gene‐predicted proteins showed evidence of increased PE risk (CRELD1, CPA4, AHSG, NFASC, QDPR, NTM, PZP, FAM171B, RTN4R, FLRT2, ADH4, ADM, SPINK5, LGALS4, CKM, SPON2, UROS, CXCL10 and APOBEC3G); 23 proteins reduced the risk of PE (CLIC5, NEO1, SWAP70, KLK8, VWA2, FSTL1, CXCL11, APOB, NPPB, CNTN4, IL12B, ACHE, TCN1, GFRA2, GNMT, HPGDS, DPT, MANBA, SPARCL1, ACE, FUT8, BST1 and ACP1). Bayesian colocalisation indicated that six proteins (VWA2, ACHE, CXCL10, PZP, AHSG and UROS) and PE, which were identified as high evidence of colocalisation with PE.ConclusionsThis study provides evidence of the causal association between genetically predicted 42 proteins associated with PE risk, which might be promising drug targets for PE.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

BST1

Basic Info

Related

Analysis